SCHEMBL29242590

SCHEMBL29242590

c1cn2c(ccc3[nH]ccc32)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.45
CDK8 P49336 2/20 0.36
ROCK1 Q13464 2/20 0.36
CHEK1 O14757 1/20 0.36
MAP4K4 O95819 1/20 0.36
CSF1R P07333 1/20 0.36
PRKACA P17612 1/20 0.36
KDR P35968 1/20 0.36
MAP2K1 Q02750 1/20 0.36
ACVR1 Q04771 1/20 0.36
MAP4K2 Q12851 1/20 0.36
DYRK1A Q13627 1/20 0.36
AURKB Q96GD4 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
DRD1 P21728 4/20 0.34
PRKCI P41743 1/20 0.34
ATR Q13535 1/20 0.33
PSMD14 O00487 1/20 0.33
FLT1 P17948 1/20 0.33
CDK9 P50750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16818755 0.74 BRD4 (0.49) BRD4
SCHEMBL1935026 0.73 KDR (0.42) CDK8ROCK1CHEK1MAP4K4CSF1R
SCHEMBL19410802 0.69 CDK8 (0.38) CDK8ROCK1CHEK1MAP4K4CSF1R
SCHEMBL557383 0.69 MAP2K1 (0.44) CDK8ROCK1CHEK1MAP4K4CSF1R
SCHEMBL20767747 0.67 CDK8 (0.36) CDK8ROCK1CHEK1MAP4K4CSF1R
SCHEMBL1104796 0.65 ROCK1 (0.46) BRD4CDK8ROCK1CHEK1MAP4K4
SCHEMBL6512398 0.65 CCNE1 (0.33) CDK8ROCK1CHEK1MAP4K4CSF1R
SCHEMBL16244139 0.64 RPS6KA5 (0.47) CDK8ROCK1CHEK1MAP4K4CSF1R
SCHEMBL24896311 0.62 RAB9A (0.49) BRD4MAP2K1MAPT
SCHEMBL1599283 0.61 MAPT (0.38) CDK8ROCK1CHEK1MAP4K4CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294529-A1 6H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRIDINE DERIVATIVES FOR USE IN THERAPY SANOFI (FR) 2024-09-05 US disclosed
US-20240294529-A1 6H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRIDINE DERIVATIVES FOR USE IN THERAPY SANOFI (FR) 2024-09-05 US disclosed
CN-118234727-A 6H-imidazo [1,2-a ] pyrrolo [2,3-e ] pyridine derivatives for use in therapy 赛诺菲 2024-06-21 CN disclosed
CN-118234727-A 6H-imidazo [1,2-a ] pyrrolo [2,3-e ] pyridine derivatives for use in therapy 赛诺菲 2024-06-21 CN disclosed
EP-4373337-A1 VAPOUR GENERATING DEVICE JT International SA (CH) 2024-05-29 EP disclosed
EP-4370516-A1 6H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRIDINE DERIVATIVES FOR USE IN THERAPY Sanofi (FR) 2024-05-22 EP disclosed
EP-4370516-A1 6H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRIDINE DERIVATIVES FOR USE IN THERAPY Sanofi (FR) 2024-05-22 EP disclosed
WO-2023285465-A1 6H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRIDINE DERIVATIVES FOR USE IN THERAPY SANOFI (FR) 2023-01-19 WO disclosed
WO-2023285465-A1 6H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRIDINE DERIVATIVES FOR USE IN THERAPY SANOFI (FR) 2023-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294529-A1 6H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRIDINE DERIVATIVES FOR USE IN THERAPY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AKR1C3, CBR3 BRD4 298/4885CDK8 1747/4885ROCK1 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.